Association of small dense LDL serum levels and circulating monocyte subsets in stable coronary artery disease

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Krychtiuk, Konstantin A ^a   Kastl, Stefan P ^b   Pfaffenberger, Stefan ^a   Lenz, Max ^a   Hofbauer, Sebastian L ^a   Wonnerth, Anna ^a   Koller, Lorenz ^a   Katsaros, Katharina M ^a   Pongratz, Thomas ^c   Goliasch, Georg ^a   Niessner, Alexander ^a   Gaspar, Ludovit ^d   Huber, Kurt ^b,e   Maurer, Gerald ^a   Dostal, Elisabeth ^c   Wojta, Johann ^a,b   Oravec, Stanislav ^c,d   Speidl, Walter S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Ludwig Boltzmann Cluster for Cardiovascular Research   (Austria)

^c Krankenanstalten Dr Dostal ^*  (Austria)

^d Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^e WILHELMINEN HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CD14 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; ROSUVASTATIN; SMALL DENSE LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; BIOLOGICAL MARKER;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL SUBPOPULATION; CELLULAR DISTRIBUTION; CLASSICAL MONOCYTE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATIONAL STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; INFLAMMATION; INTERMEDIATE MONOCYTE; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOCYTE; NON CLASSICAL MONOCYTE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROGNOSIS; PROTEIN DETERMINATION; AGED; BLOOD; CLINICAL TRIAL; CORONARY ANGIOGRAPHY; CROSS-SECTIONAL STUDY; PATHOLOGY;

AGED; BIOMARKERS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; FLOW CYTOMETRY; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MONOCYTES;

EID: 84927559038     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123367     Document Type: Article

References (47)

1. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011; 12(3):204-12. Epub 2011/02/16. ni.2001 [pii] doi: 10.1038/ni.2001 PubMed PMID: 21321594.
2. Krychtiuk KA, Kastl SP, Speidl WS, Wojta J. Inflammation and coagulation in atherosclerosis. Hamostaseologie. 2013; 33(4):269-82. doi: 10.5482/HAMO-13-07-0039 PubMed PMID: 24043155.
3. Passlick B, Flieger D, Ziegler-Heitbrock HW. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood. 1989; 74(7):2527-34. Epub 1989/11/15. PubMed PMID: 2478233.
4. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, et al. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010; 116(16):e74-80. Epub 2010/07/16. blood-2010-02-258558 [pii] doi: 10.1182/blood-2010-02-258558 PubMed PMID: 20628149.
5. Zawada AM, Rogacev KS, Schirmer SH, Sester M, Bohm M, Fliser D, et al. Monocyte heterogeneity in human cardiovascular disease. Immunobiology. 2012; 217(12):1273-84. Epub 2012/08/18. S0171-2985(12)00155-6 [pii] doi: 10.1016/j.imbio.2012.07.001 PubMed PMID: 22898391.
6. Belge KU, Dayyani F, Horelt A, Siedlar M, Frankenberger M, Frankenberger B, et al. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol. 2002; 168(7):3536-42. Epub 2002/03/22. PubMed PMID: 11907116.
7. Hristov M, Weber C. Differential role of monocyte subsets in atherosclerosis. Thrombosis and haemostasis. 2011; 106(5):757-62. Epub 2011/09/09. 11-07-0500 [pii] doi: 10.1160/TH11-07-0500 PubMed PMID: 21901241.
8. Schlitt A, Heine GH, Blankenberg S, Espinola-Klein C, Dopheide JF, Bickel C, et al. CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. Thrombosis and haemostasis. 2004; 92(2):419-24. Epub 2004/07/23. doi: 10.1267/THRO04080419 04080419 [pii]. PubMed PMID: 15269840.
9. Rogacev KS, Ulrich C, Blomer L, Hornof F, Oster K, Ziegelin M, et al. Monocyte heterogeneity in obesity and subclinical atherosclerosis. Eur Heart J. 2010; 31(3):369- 76. Epub 2009/08/19. ehp308 [pii] doi: 10.1093/eurheartj/ehp308 PubMed PMID: 19687164.
10. Poitou C, Dalmas E, Renovato M, Benhamo V, Hajduch F, Abdennour M, et al. CD14dimCD16+ and CD14+CD16+ monocytes in obesity and during weight loss: relationships with fat mass and subclinical atherosclerosis. Arterioscler Thromb Vasc Biol. 2011; 31(10):2322-30. Epub 2011/07/30. ATV-BAHA. 111.230979 [pii] doi: 10.1161/ATVBAHA.111.230979 PubMed PMID: 21799175.
11. Rothe G, Gabriel H, Kovacs E, Klucken J, Stohr J, Kindermann W, et al. Peripheral blood mononuclear phagocyte subpopulations as cellular markers in hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1996; 16(12):1437-47. Epub 1996/12/01. PubMed PMID: 8977447.
12. Rothe G, Herr AS, Stohr J, Abletshauser C, Weidinger G, Schmitz G. A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease. Atherosclerosis. 1999; 144(1):251-61. Epub 1999/06/25. S0021-9150(99) 00061-1 [pii]. PubMed PMID: 10381298.
13. Rogacev KS, Cremers B, Zawada AM, Seiler S, Binder N, Ege P, et al. CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol. 2012; 60(16):1512-20. Epub 2012/09/25. S0735-1097(12)02813-6 [pii] doi: 10.1016/j.jacc.2012.07.019 PubMed PMID: 22999728.
14. Ross R, Harker L. Hyperlipidemia and atherosclerosis. Science. 1976; 193(4258):1094-100. Epub 1976/09/17. PubMed PMID: 822515.
15. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011; 217(1):3-46. PubMed PMID: 21882396.
16. Packard CJ. Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Current opinion in lipidology. 2006; 17(4):412-7. doi: 10.1097/01.mol.0000236367.42755.c1 PubMed PMID: 16832165.
17. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. Journal of lipid research. 1982; 23(1):97-104. PubMed PMID: 7057116.
18. Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation. 2002; 106(15):1930-7. Epub 2002/10/09. PubMed PMID: 12370215.
19. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996; 276(11):875-81. Epub 1996/09/18. PubMed PMID: 8782636.
20. El Harchaoui K, van der Steeg WA, Stroes ES, Kuivenhoven JA, Otvos JD, Wareham NJ, et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007; 49(5):547-53. Epub 2007/02/06. S0735-1097(06)02863-4 [pii] doi: 10.1016/j.jacc.2006.09.043 PubMed PMID: 17276177.
21. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. Journal of lipid research. 2002; 43(9):1363-79. PubMed PMID: 12235168.
22. Goliasch G, Oravec S, Blessberger H, Dostal E, Hoke M, Wojta J, et al. Relative importance of different lipid risk factors for the development of myocardial infarction at a very young age (
23. Hoefner DM, Hodel SD, O'Brien JF, Branum EL, Sun D, Meissner I, et al. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem. 2001; 47(2):266-74. Epub 2001/02/13. PubMed PMID: 11159775.
24. Arbab-Zadeh A, Nakano M, Virmani R, Fuster V. Acute coronary events. Circulation. 2012; 125 (9):1147-56. Epub 2012/03/07. 125/9/1147 [pii] doi: 10.1161/CIRCULATIONAHA.111.047431 PubMed PMID: 22392862; PubMed Central PMCID: PMC3322378.
25. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol. 2010; 30(7):1282-92. Epub 2010/06/18. 30/7/1282 [pii] doi: 10.1161/ATVBAHA.108.179739 PubMed PMID: 20554950.
26. Ghattas A, Griffiths HR, Devitt A, Lip GY, Shantsila E. Monocytes in coronary artery disease and atherosclerosis: where are we now? Journal of the American College of Cardiology. 2013; 62(17):1541-51. doi: 10.1016/j.jacc.2013.07.043 PubMed PMID: 23973684.
27. Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. Journal of leukocyte biology. 2007; 81(3):584-92. doi: 10.1189/jlb.0806510 PubMed PMID: 17135573.
28. Kashiwagi M, Imanishi T, Tsujioka H, Ikejima H, Kuroi A, Ozaki Y, et al. Association of monocyte subsets with vulnerability characteristics of coronary plaques as assessed by 64-slice multidetector computed tomography in patients with stable angina pectoris. Atherosclerosis. 2010; 212(1):171-6. Epub 2010/08/06. S0021-9150(10)00334-5 [pii] doi: 10.1016/j.atherosclerosis.2010.05.004 PubMed PMID: 20684824.
29. Imanishi T, Ikejima H, Tsujioka H, Kuroi A, Ishibashi K, Komukai K, et al. Association of monocyte subset counts with coronary fibrous cap thickness in patients with unstable angina pectoris. Atherosclerosis. 2010; 212(2):628-35. Epub 2010/07/10. S0021-9150(10)00443-0 [pii] doi: 10.1016/j.atherosclerosis.2010.06.025 PubMed PMID: 20615506.
30. Rogacev KS, Seiler S, Zawada AM, Reichart B, Herath E, Roth D, et al. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J. 2011; 32(1):84-92. Epub 2010/10/15. ehq371 [pii] doi: 10.1093/eurheartj/ehq371 PubMed PMID: 20943670.
31. Heine GH, Ulrich C, Seibert E, Seiler S, Marell J, Reichart B, et al. CD14(++)CD16+ monocytes but not total monocyte numbers predict cardiovascular events in dialysis patients. Kidney Int. 2008; 73(5):622-9. Epub 2007/12/28. 5002744 [pii] doi: 10.1038/sj.ki.5002744 PubMed PMID: 18160960.
32. Berg KE, Ljungcrantz I, Andersson L, Bryngelsson C, Hedblad B, Fredrikson GN, et al. Elevated CD14 ++CD16- monocytes predict cardiovascular events. Circ Cardiovasc Genet. 2012; 5(1):122-31. Epub 2012/01/13. CIRCGENETICS.111.960385 [pii] doi: 10.1161/CIRCGENETICS.111.960385 PubMed PMID: 22238190.
33. Mosig S, Rennert K, Krause S, Kzhyshkowska J, Neunubel K, Heller R, et al. Different functions of monocyte subsets in familial hypercholesterolemia: potential function of CD14+ CD16+ monocytes in detoxification of oxidized LDL. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2009; 23(3):866-74. doi: 10.1096/fj.08-118240 PubMed PMID: 19001052.
34. Kapinsky M, Torzewski M, Buchler C, Duong CQ, Rothe G, Schmitz G. Enzymatically degraded LDL preferentially binds to CD14(high) CD16(+) monocytes and induces foam cell formation mediated only in part by the class B scavenger-receptor CD36. Arterioscler Thromb Vasc Biol. 2001; 21(6):1004-10. PubMed PMID: 11397711.
35. Draude G, von Hundelshausen P, Frankenberger M, Ziegler-Heitbrock HW, Weber C. Distinct scavenger receptor expression and function in the human CD14(+)/CD16(+) monocyte subset. The American journal of physiology. 1999; 276(4 Pt 2):H1144-9. PubMed PMID: 10199836.
36. Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753):1670-81. doi: 10.1016/S0140-6736(10) 61350-5 PubMed PMID: 21067804; PubMed Central PMCID: PMC2988224.
37. Anber V, Griffin BA, McConnell M, Packard CJ, Shepherd J. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis. 1996; 124(2):261-71. PubMed PMID: 8830938.
38. Dejager S, Bruckert E, Chapman MJ. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. Journal of lipid research. 1993; 34(2):295-308. PubMed PMID: 8429263.
39. Campos H, Genest JJ Jr., Blijlevens E, McNamara JR, Jenner JL, Ordovas JM, et al. Low density lipoprotein particle size and coronary artery disease. Arteriosclerosis and thrombosis: a journal of vascular biology / American Heart Association. 1992; 12(2):187-95. PubMed PMID: 1543692.
40. Hoogeveen RC, Gaubatz JW, Sun W, Dodge RC, Crosby JR, Jiang J, et al. Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease: The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol. 2014. doi: 10.1161/ATVBAHA.114.303284 PubMed PMID: 24558110.
41. Coen PM, Flynn MG, Markofski MM, Pence BD, Hannemann RE. Adding exercise to rosuvastatin treatment: influence on C-reactive protein, monocyte toll-like receptor 4 expression, and inflammatory monocyte (CD14+CD16+) population. Metabolism: clinical and experimental. 2010; 59(12):1775-83. doi: 10.1016/j.metabol.2010.05.002 PubMed PMID: 20580035.
42. Jaipersad AS, Shantsila E, Blann A, Lip GY. The effect of statin therapy withdrawal on monocyte subsets. Eur J Clin Invest. 2013; 43(12):1307-13. doi: 10.1111/eci.12183 PubMed PMID: 24134608.
43. Fildes JE, Shaw SM, Mitsidou A, Rogacev K, Leonard CT, Williams SG, et al. HMG-CoA reductase inhibitors deplete circulating classical and non-classical monocytes following human heart transplantation. Transplant immunology. 2008; 19(2):152-7. doi: 10.1016/j.trim.2008.02.002 PubMed PMID: 18503891.
44. Kirmizis D, Papagianni A, Dogrammatzi F, Skoura L, Belechri AM, Alexopoulos E, et al. Effects of simvastatin on markers of inflammation, oxidative stress and endothelial cell apoptosis in patients on chronic hemodialysis. Journal of atherosclerosis and thrombosis. 2010; 17(12):1256-65. PubMed PMID: 20885069.
45. St-Pierre AC, Bergeron J, Pirro M, Cantin B, Dagenais GR, Despres JP, et al. Effect of plasma C-reactive protein levels in modulating the risk of coronary heart disease associated with small, dense, lowdensity lipoproteins in men (The Quebec Cardiovascular Study). The American journal of cardiology. 2003; 91(5):555-8. PubMed PMID: 12615259.
46. West SD, Goldberg D, Ziegler A, Krencicki M, Du Clos TW, Mold C. Transforming growth factor-beta, macrophage colony-stimulating factor and C-reactive protein levels correlate with CD14(high)CD16+ monocyte induction and activation in trauma patients. PloS one. 2012; 7(12):e52406. doi: 10.1371/journal.pone.0052406 PubMed PMID: 23285029; PubMed Central PMCID: PMC3532215.
47. Horelt A, Belge KU, Steppich B, Prinz J, Ziegler-Heitbrock L. The CD14+CD16+ monocytes in erysipelas are expanded and show reduced cytokine production. European journal of immunology. 2002; 32(5):1319-27. doi: 10.1002/1521-4141(200205)32:5〈1319::AID-IMMU1319〉3.0.CO;2-2 PubMed PMID: 11981819.